Trial Profile
Phase IIb, placebo controlled clinical trial of ReN-003 in the patients with retinitis pigmentosa
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs ReN 003 (Primary)
- Indications Retinitis pigmentosa
- Focus Therapeutic Use
- 01 Oct 2021 According to a ReNeuron medis release, the company expects to initiate this trial by the end of 2022.
- 22 Dec 2017 New trial record
- 14 Dec 2017 According to a ReNeuron medis release, IND application has been approved to commence this trial in H1 2018.